Pelthos Therapeutics (PTHS) The 38th Annual Roth Conference summary

Corporate history and capitalization

• Merged into Channel Therapeutics and rebranded as Pelthos on July 1, 2025, leveraging brand equity with prescribers.

• Raised $50 million PIPE and began trading on NYSE as PTHS.

• As-converted share count is about 8.9 million, with a market cap near $200 million.

Lead product overview and market need

• ZELSUVMI is the first and only FDA-approved at-home topical for molluscum contagiosum, indicated for patients one year and older.

• Prior treatments were destructive, office-based procedures, often requiring multiple visits.

• ZELSUVMI offers daily topical application for up to 12 weeks, with strong efficacy and safety.

Commercial performance and prescriber trends

• Prescription volume grew 129% from Q3 to Q4, with net revenue rising from $7.1M to $9.1M.

• Over 4,200 unique prescribers since launch in July 2025, with acceleration in early 2026.